Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that Dutasteride, a 5α-reductase inhibitor, demonstrated neuroprotective effects by preventing the MPTP-induced decline of dopaminergic markers in a Parkinson's disease mouse model.

This study observed that a self-emulsifying drug delivery system for finasteride significantly enhanced bioavailability in rats compared to commercial tablets, but the formulation was found to be thermodynamically unstable.

This study evaluated the quality of 5% Minoxidil samples and found that only one out of three magistral formulations met acceptance criteria, highlighting the need for stricter quality control in custom pharmacy preparations to ensure their therapeutic efficacy.

In this in vitro study, pretreatment with Dead Sea water and saline magnetized water reduced UVB-induced DNA damage and inflammation markers in human keratinocyte cells, primarily through autophagy activation, suggesting potential use in topical products to prevent skin damage from UV exposure.

Dutasteride helps reduce male pattern hair loss, but may cause side effects like altered libido and erectile dysfunction.

This article describes a case of dyschromatosis universalis in a young Saudi Arabian girl, discussing similar cases reported outside the Far East where the condition was initially identified, but provides no new research findings.

This study identified genetic variations in the DSG4 gene among sheep, revealing valuable markers for assessing their impact on wool traits.

This study demonstrated that CD anisotropy effectively distinguishes between two polymorphs of finasteride with nearly identical electronic circular dichroism spectra, using imaging and simulated spectra to uncover unique signatures that traditional methods miss.

This review discusses the transformative potential of direct-to-consumer (DTC) hair regrowth solutions and reports no clinical results; it emphasizes innovation, personalization, and trust in reshaping the industry.

This article discusses finasteride and dutasteride use for androgenetic alopecia in light of recent concerns over persistent erectile dysfunction but provides no new clinical findings.

This study found that teledermatology significantly reduced wait times and increased appointment availability for uninsured Latino immigrants, effectively triaging 70% of cases without in-person visits.

This study explored the use of SOD-loaded niosomes as carriers to enhance the delivery of superoxide dismutase into hair follicles on guinea pig skin, finding that niosomes improved SOD penetration and preservation compared to free SOD, suggesting their potential as effective delivery vehicles.

This study found that in Japanese male patients with androgenetic alopecia, dutasteride 0.5 mg daily over 52 weeks was associated with improvements in hair growth and appearance, with reported adverse events mostly mild.

This pilot study found that using skin patting and iontophoresis to deliver a 6% dutasteride gel led to significant improvements in hair density and shaft diameter in men and postmenopausal women with treatment-resistant androgenetic alopecia, with no reported adverse events.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

This study found that dutasteride-loaded nanostructured lipid carriers coated with a stearic acid-chitosan oligomer are stable, less cytotoxic, and suitable for topical delivery to promote hair growth.

This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.

This study reported that a novel vasodilator drug called TOP-M119, when delivered using a specially designed dissolving microneedle system, showed enhanced targeting of hair follicles and effectiveness in treating alopecia, demonstrated through in vitro, ex vivo, and in vivo studies involving mouse skin.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

This study reports the development of a fluorescent ionic liquid that shows high sensitivity and selectivity for detecting dextran sulfate sodium, with potential applications in clinical diagnostics and environmental monitoring.

In this study, both finasteride and dutasteride were effective for androgenetic alopecia, but dutasteride significantly improved hair density more than finasteride and had a comparable safety profile among men treated at an Indian center.